The Effect of Escitalopram on the Pharmacokinetics and Pharmacodynamics of Tramadol in Healthy Subjects

Phase 4 Completed 15 enrolled University of Southern Denmark H. Lundbeck A/S · collab

RandomizedCrossoverTriple-blindTreatment

Summary

Escitalopram will be given to a panel of 16 healthy subject for 9 days. On the ninth day a single dose of tramadol is administered to the subjects and pharmacokinetic(PK) and pharmacodynamic(PD) measurements are done for the next 24 hours. It is stated that escitalopram is only a weak inhibitor of CYP2D6 and therefore no effect is seen in Pk or PK of tramadol

Timeline

Start: 2008-02
Primary completion: 2008-08
Completion: 2008-08

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Escitalopram	Small molecule	20 mg	—
Subject	Tramadol	Other / unclassified	150 mg	—

Indications

No indication recorded.